Levemopamil | CAS#101238-51-1 | calcium-channel blocker

MedKoo Cat#: 598711 | Name: Levemopamil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levemopamil is a calcium-channel blocker.

Chemical Structure

Levemopamil

CAS#101238-51-1

Theoretical Analysis

MedKoo Cat#: 598711

Name: Levemopamil

CAS#: 101238-51-1

Chemical Formula: C23H30N2

Exact Mass: 334.2409

Molecular Weight: 334.50

Elemental Analysis: C, 82.59; H, 9.04; N, 8.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Levemopamil; Levemopamilo;

IUPAC/Chemical Name

(S)-2-isopropyl-5-(methyl(phenethyl)amino)-2-phenylpentanenitrile

InChi Key

DWAWDSVKAUWFHC-QHCPKHFHSA-N

InChi Code

InChI=1S/C23H30N2/c1-20(2)23(19-24,22-13-8-5-9-14-22)16-10-17-25(3)18-15-21-11-6-4-7-12-21/h4-9,11-14,20H,10,15-18H2,1-3H3/t23-/m0/s1

SMILES Code

N#C[C@](C1=CC=CC=C1)(C(C)C)CCCN(C)CCC2=CC=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fleischer JE, Nakakimura K, Drummond JC, Scheller MS, Zornow MH, Grafe MR, Shapiro HM. Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats. Crit Care Med. 1992 Jan;20(1):126-34. PubMed PMID: 1729030. 2: Heim C, Sieklucka M, Sontag KH. Levemopamil injection after cerebral oligemia reduces spatial memory deficits in rats. Pharmacol Biochem Behav. 1994 Jul;48(3):613-9. PubMed PMID: 7938114. 3: Elger B, Seega J, Raschack M. Oedema reduction by levemopamil in focal cerebral ischaemia of spontaneously hypertensive rats studied by magnetic resonance imaging. Eur J Pharmacol. 1994 Mar 11;254(1-2):65-71. PubMed PMID: 8206118. 4: Elger B, Seega J, Brendel R. Magnetic resonance imaging study on the effect of levemopamil on the size of intracerebral hemorrhage in rats. Stroke. 1994 Sep;25(9):1836-41. PubMed PMID: 8073466. 5: Sano T, Patel PM, Drummond JC, Cole DJ. Combined therapy with dizocilpine and levemopamil does not reduce ischemic neuronal injury in rats. J Neurosurg Anesthesiol. 1993 Jul;5(3):194-201. PubMed PMID: 8400759. 6: Rezvani AH, Pucilowski O, Grady DR, Janowsky D, O'Brien RA. Reduction of spontaneous alcohol drinking and physical withdrawal by levemopamil, a novel Ca2+ channel antagonist, in rats. Pharmacol Biochem Behav. 1993 Oct;46(2):365-71. PubMed PMID: 8265691. 7: Myrdal PB, Simamora P, Surakitbanharn Y, Yalkowsky SH. Studies in phlebitis. VII: In vitro and in vivo evaluation of pH-solubilized levemopamil. J Pharm Sci. 1995 Jul;84(7):849-52. PubMed PMID: 7562436. 8: Seega J, Elger B. Diffusion- and T2-weighted imaging: evaluation of oedema reduction in focal cerebral ischaemia by the calcium and serotonin antagonist levemopamil. Magn Reson Imaging. 1993;11(3):401-9. PubMed PMID: 8505874. 9: Block F, Szabo L, Jaspers RM, Heim C, Sontag KH. Levemopamil reduces spatial learning deficit following transient occlusion of common carotid arteries in normotensive rats. Acta Neurol Scand. 1993 Jul;88(1):35-40. PubMed PMID: 8372627. 10: Gomi S, Greenberg JH, Croul S, Reivich M. Failure of levemopamil to improve histological outcome following temporary occlusion of the middle cerebral artery in cats. J Neurol Sci. 1995 Jun;130(2):128-33. PubMed PMID: 8586975. 11: Toyohara J, Okamoto M, Aramaki H, Zaitsu Y, Shimizu I, Ishiwata K. (R)-[¹¹C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. Nucl Med Biol. 2016 Jan;43(1):52-62. doi: 10.1016/j.nucmedbio.2015.09.001. Epub 2015 Sep 7. PubMed PMID: 26429767. 12: McCandless R, Yalkowsky SH. Effect of hydroxypropyl-beta-cyclodextrin and pH on the solubility of levemopamil HCl. J Pharm Sci. 1998 Dec;87(12):1639-42. PubMed PMID: 10189280. 13: Ozyurt K, Subasioglu A, Ozturk P, Inci R, Ozkan F, Bueno E, Cañueto J, González Sarmiento R. Emopamil binding protein mutation in conradi-hünermann-happle syndrome representing plaque-type psoriasis. Indian J Dermatol. 2015 Mar-Apr;60(2):216. doi: 10.4103/0019-5154.152570. PubMed PMID: 25814754; PubMed Central PMCID: PMC4372958. 14: Kramer HJ, Rosberg J, Bäcker A, Meyer-Lehnert H. Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54. PubMed PMID: 8882635; PubMed Central PMCID: PMC1909804. 15: Rossi M, Hall CM, Bouvier R, Collardeau-Frachon S, Le Breton F, Bucourt M, Cordier MP, Vianey-Saban C, Parenti G, Andria G, Le Merrer M, Edery P, Offiah AC. Radiographic features of the skeleton in disorders of post-squalene cholesterol biosynthesis. Pediatr Radiol. 2015 Jul;45(7):965-76. doi: 10.1007/s00247-014-3257-9. Epub 2015 Feb 3. Review. PubMed PMID: 25646736. 16: Block F, Schwarz M. Global ischemic neuronal damage relates to behavioural deficits: a pharmacological approach. Neuroscience. 1998 Feb;82(3):791-803. PubMed PMID: 9483536. 17: Barboza-Cerda MC, Wong LJ, Martínez-de-Villarreal LE, Zhang VW, Déctor MA. A novel EBP c.224T>A mutation supports the existence of a male-specific disorder independent of CDPX2. Am J Med Genet A. 2014 Jul;164A(7):1642-7. doi: 10.1002/ajmg.a.36508. Epub 2014 Apr 3. PubMed PMID: 24700572. 18: Hartill VL, Tysoe C, Manning N, Dobbie A, Santra S, Walter J, Caswell R, Koster J, Waterham H, Hobson E. An unusual phenotype of X-linked developmental delay and extreme behavioral difficulties associated with a mutation in the EBP gene. Am J Med Genet A. 2014 Apr;164A(4):907-14. doi: 10.1002/ajmg.a.36368. Epub 2014 Jan 23. PubMed PMID: 24459067. 19: Rossokhin A, Dreker T, Grissmer S, Zhorov BS. Why does the inner-helix mutation A413C double the stoichiometry of Kv1.3 channel block by emopamil but not by verapamil? Mol Pharmacol. 2011 Apr;79(4):681-91. doi: 10.1124/mol.110.068031. Epub 2011 Jan 10. PubMed PMID: 21220411. 20: Kuo JR, Shang HS, Ho CT, Lai KG, Liu TZ, Chen YJ, Chiou JF. Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: Potential application for therapeutic targeting. Oncol Lett. 2016 Nov;12(5):3723-3730. Epub 2016 Sep 23. PubMed PMID: 27895723; PubMed Central PMCID: PMC5104157.